23andMe Holding Co. (MEUSW)

Overview

23andMe Holding Co. is renowned for its pioneering efforts in consumer genetics testing, embodying a unique blend of healthcare and biotechnology. Founded in 2006 and based in South San Francisco, California, the company has grown to operate across two vital segments: Consumer & Research Services and Therapeutics. Through its innovative approach, 23andMe leverages genetic data to offer insightful reports on ancestry, health risks, and medication responses, while also making strides in the development of novel therapies aimed at transforming patient care in areas such as oncology, respiratory, and cardiovascular diseases.

Products and Services

• Genetic Reports

  This service delivers comprehensive insights into an individual's genetic ancestral origins, personal health risks, carrier status for rare conditions, and how genetics can influence drug responses. It serves as a foundation for personalized healthcare and wellness planning.

• Lemonaid Telehealth Platform

  An integral part of the Consumer & Research Services segment, the Lemonaid platform connects users with licensed healthcare professionals for consultations and treatments addressing common conditions. This service underscores 23andMe's commitment to making healthcare more accessible and tailored to individual needs.

• Research Services

  23andMe extends its capabilities to offer research services, leveraging the vast genetic data obtained from consenting customers to fuel studies that advance the understanding of human genetics and health. These efforts not only contribute to the scientific community but also refine the company's consumer offerings.

• Drug Development in Therapeutics Segment

  The Therapeutics segment is dedicated to the discovery and development of innovative drugs. It emphasizes patient-centric solutions across several therapeutic areas, including oncology, respiratory diseases, and cardiovascular conditions. By harnessing genetic insights, 23andMe aims to revolutionize the approach to disease treatment and prevention.

• 23ME-00610 (P006)

  This humanized monoclonal antibody, currently in phase 1/2a clinical trials, targets the interaction between CD200R1 and CD200 in cancer cells. It represents 23andMe's commitment to developing treatments that directly interfere with cancer cell mechanisms, showcasing the potential of genetics-based therapeutics.

• GSK6097608

  An antibody that zeroes in on CD96, aiming to enhance T and NK cell anti-tumor immune responses. This product is a testament to the company's efforts to develop therapies that harness the body's immune system to fight cancer more effectively.